Landos Biopharma Completes $60 Million Series B Financing (IMAGE)

LaVoieHealthScience

Landos Biopharma Completes $60 Million Series B Financing

Caption

This financing is an important part of our strategy to advance lead product BT-11 into global Phase 2 clinical trials for ulcerative colitis and Crohn's disease.

Credit

Landos Biopharma

Usage Restrictions

None

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.